Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.
The AL amyloidosis market is expected to show positive growth owing to the factors such as increased incidence and the anticipated launch of novel therapies during the forecast period (2019-2032). LAS